Louisville, Kentucky (PRWEB) May 10, 2012
Cymbion, LLC has released a technical bulletin on its patented LiquiCleanse® hand sanitizer. For the first time since the product’s inception nearly a decade ago, Cymbion has agreed to reveal results of FDA-mandated efficacy testing, skin sensitivity testing, and end user surveys collected over the past decade.
After conducting extensive research on human skin physiology and barriers to hand hygiene compliance, the Research and Development team at Cymbion created LiquiCleanse® hand sanitizer. Primary research involving a large number of patient-facing healthcare workers indicated common barriers to compliance included an unpleasant tactile response during use of hand sanitizers, long drying times, xerosis with repeated use, and the presence of product residue on hands. LiquiCleanse® hand sanitizer contains 81 percent alcohol by volume yet does not leave skin dry. The formulation is water-free to eliminate the need for carbomers, pH buffers, and other ingredients that leave a residue but are non-essential to the primary function of hand sanitizer. The patented formulation also allows LiquiCleanse® to evaporate at the same rate, regardless of temperature or ambient humidity, without the cooling effect common to hand sanitizers.
Independent testing performed by an independent national laboratory confirmed that LiquiCleanse® meets or exceeds FDA standards for a healthcare hand antiseptic, achieving a greater than 3 log reduction in the marker organism in only one application. Repeat Insult Patch Testing concluded that the formula did not cause contact sensitivity. Cymbion strongly believes that the LiquiCleanse® formula is the perfect storm of safety and efficacy needed to combat non-compliance with hand hygiene protocols.
While other hand sanitizers’ product literature indicates an effective application volume of 1-2mL, LiquiCleanse® hand sanitizer has a significantly lower application volume, dispensed as a spray. “We have raised the bar with regard to product value,” stated Cymbion, LLC President Dr. Vinod K. Narula, MD. “In our years of research, we have not found another hand sanitizer that can deliver an effective application of this magnitude.”
LiquiCleanse® hand sanitizer has been available in limited distribution for nearly a decade. Cymbion reports that they have continuously collected survey data from a wide demographic of uncompensated respondents in order to evaluate on-going user acceptance and preferences. Their latest data trends indicate a universal acceptance rate among healthcare workers, students, skilled and unskilled laborers, professionals, and the elderly. “We understand that every product has its detractors,” stated Dr. Narula. “The unprecedented positive response rates we have received tell us that the hard work we have put into the development of LiquiCleanse® was not in vain. The whole point of creating this product was to improve everyday life in a small way. Our success is not measured in revenue flow, industry accolades, or the size of our advertising budget. Success is when one person shakes my hand and tells me he or she loves our product. It is a most humbling and awe-inspiring experience.”
A copy of the technical bulletin may be obtained through the Cymbion Professional website at http://www.cymbionllc.com. LiquiCleanse® hand sanitizer is available to professionals and consumers through Cymbion, LLC distribution partners. Businesses interested in learning more about Cymbion products can visit the Cymbion Professional website. Consumers interested in learning more about the LiquiCleanse® product line can visit http://www.liquicleanse.com.
About Cymbion, LLC
Cymbion, LLC is a medical device manufacturer based in Louisville, Kentucky. Cymbion focuses on products addressing everyday challenges, finding ingenious ways to improve health, safety, and quality of life.